Price Alert

Apogee Therapeutics Inc. (APGE)

NASDAQ: APGE · Real-Time Price · USD

37.10

-0.42 (-1.12%)

At close: Sep 26, 2025, 11:05 AM

-1.12% (1D)

Bid	37.03
Market Cap	2.17B
Revenue (ttm)	130K
Net Income (ttm)	-171.57M
EPS (ttm)	-4.14
PE Ratio (ttm)	-8.96
Forward PE	-6.87
Analyst	Buy
Dividends	n/a

Ask	37.17
Volume	77,932
Avg. Volume (20D)	790,992
Open	38.03
Previous Close	37.52
Day's Range	36.85 - 38.03
52-Week Range	26.20 - 63.50
Beta	1.43
Ex-Dividend Date	n/a

About APGE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol APGE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for APGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-17.32%

APGE stock has given up its prior gain. Apogee The... Unlock content with Pro Subscription

2 months ago

-17.32%

Apogee Therapeutics shares are trading higher after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.

News

1 month ago · zacks.com

Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questi...

2 months ago · seekingalpha.com

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact...

2 months ago · proactiveinvestors.com

Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug

Apogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The tr...